RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 PARAMOUNT Trial Results
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 13
SP 11
OP 12
DO 10.1177/155989771213003
UL http://mdc.sagepub.com/content/12/13/11.abstract
AB In about half of all patients with heart failure (HF), the ejection fraction (EF) is normal or nearly normal, despite high morbidity and mortality in these patients. Now, the findings of a Phase 2 trial suggest that a first-in-class angiotensin receptor neprilysin inhibitor, LCZ696, may be beneficial for patients who have HF with preserved EF. This article discusses the Prospective Comparison of ARNI with ARB (angiotensin receptor blocker) on Management of Heart Failure with Preserved Ejection Fraction [PARAMOUNT; NCT00887588] trial.